ILLUMINA, INC.

Illumina, Inc. develops and provides genetic analysis solutions, focusing on sequencing- and microarray-based technologies. The company supplies integrated platforms, specialized instruments, and consumable reagents that enable researchers and healthcare specialists to analyze genetic variation and biological function. Its offerings support a broad range of life science applications, including clinical diagnostics, oncology, reproductive health, and genomics research. Customers primarily include academic and research institutions, clinical laboratories, pharmaceutical and biotechnology companies, and genomic centers.

The company operates globally across several major geographic regions, including the Americas, Europe, China, and the Asia-Pacific, Middle East, and Africa regions. In addition to its domestic presence in the United States, it conducts international business and maintains accounts and operations in jurisdictions such as Singapore and the United Kingdom. Illumina maintains its principal executive headquarters in San Diego, California.

Summary of the business section of Illumina's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“The modifications affected 52 employees with units granted in 2019, which resulted in total incremental share-based compensation cost of approximately $ 41 million, and 72 employees with units granted in 2020, which resulted in total incremental share-based compensation cost of approximately $ 65 million.”